Price Competition and Falling Selling Prices
First written in FY2016. 12 of 20 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 36 of 84 companies on the "Worse" side.
107 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「In the industrial tape market, the sales environment remained challenging because of intensifying market competition, changes in the external environment and other factors.」
It continues to describe a challenging sales environment resulting from intensifying market competition and changes in the external environment. - FY2024-Q2MaterialisedAnnual report
「Sales of dressings fell below the same period of the previous year because distribution volumes declined as some medical institutions shifted to lower-priced products from other companies.」
The price competition risk has materialized as medical institutions shifting to lower-priced products from other companies and sales of dressings falling below the previous year. - FY2024-Q1WorsenedAnnual report
「Sales of the Caterie PlusTM series of wound dressings fell below the same period of the previous year because of the impact of a shift to lower-priced overseas products from other companies.」
The price competition risk has materialized as sales of Caterie Plus falling below the previous year because of a shift to lower-priced overseas products from other companies. - FY2023-Q3WorsenedAnnual report
「In the stationery and office supplies market, the sales environment remained challenging as sluggish demand for office supplies continued, amid cooling consumer sentiment caused by inflation stemming from higher raw material prices and a weaker yen, as well as the trend toward stronger private-label offerings by major distributors.」
In addition to the previously identified demand stagnation and price competition, it specifies stronger private-label offerings by major distributors as a factor worsening the sales environment. - FY2022Risk assessment disclosedAnnual report
「Risk of price competition Likelihood: Low Impact: Low」
The price competition risk has been reorganized from a description of the market environment into a key risk classified by likelihood and impact. - FY2021ReframedAnnual report
「To mitigate the risk of price competition, we continually seek to strengthen our brand and differentiate ourselves from other companies by providing, in a timely manner, high-performance, high-value-added products that are based on our distinctive advanced technologies and reliable quality and take the global environment into consideration.」
The price competition risk is organized by likelihood and impact, with brand enhancement and differentiation through high-performance, high-value-added products identified as countermeasures. - FY2021-Q1RestatedAnnual report
「During the first three months of the fiscal year, there were no significant changes in the occurrence of the major risks that management recognizes as potentially having a material impact on the financial position, operating results and cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes in the key risks, including price competition and declines in selling prices. - FY2020-Q3RestatedAnnual report
「In the OTC drug market, centered on drugstores, uncertainty over the outlook for industry restructuring continued, including the start of discussions on business integration among major drugstore chains. Against this backdrop, sales of the high-performance adhesive bandage CareleavesTM series exceeded the previous year, following the launch of television commercials for CareleavesTM Heal ForceTM and the Green and Blue CareleavesTM Heal ForceTM campaign to raise awareness. However, sales of the analgesic and anti-inflammatory Roihi TsubokoTM series fell significantly below the previous year because of a sharp decline in inbound demand following the deterioration in Japan-Korea relations.」
It continues to state that, amid ongoing uncertainty over industry restructuring in the OTC drug market, sales of Roihi Tsuboko fell below the previous year because of sluggish inbound demand. - FY2020-Q2WorsenedAnnual report
「However, sales of the analgesic and anti-inflammatory Roihi TsubokoTM series fell significantly below the previous year because of a sharp decline in inbound demand following the deterioration in Japan-Korea relations.」
In addition to risks in the retail and OTC drug markets, the sharp decline in inbound demand following the deterioration in Japan-Korea relations has materialized as sales falling below the previous year. - FY2020-Q1WorsenedAnnual report
「In the OTC drug market, centered on drugstores, uncertainty over the outlook for industry restructuring continued, including the start of discussions on business integration among major drugstore chains. For the Roihi TsubokoTM series, television commercials were aired intermittently from May, but sales fell below the previous year because of sluggish inbound demand.」
It newly specifies uncertainty over industry restructuring resulting from business integration discussions among major drugstore chains, as well as sluggish inbound demand and sales below the previous year. - FY2019-Q3RestatedAnnual report
「In the OTC drug market, centered on drugstores, in addition to the impact of business alliances among major drugstore chains and retail price competition for certain pharmaceuticals and products, market conditions remained stagnant because of the impact of natural disasters and delayed recovery in inbound demand.」
It continues to describe a sales environment affected by ongoing alliances among major drugstore chains and retail price competition, adding the impact of natural disasters and delayed recovery in inbound demand. - FY2019-Q2RestatedAnnual report
「In the OTC drug market, centered on drugstores, in addition to the impact of business alliances among major drugstore chains and retail price competition for certain pharmaceuticals and products, the market was also affected by natural disasters and stagnant inbound demand due to a temporary decline in foreign visitors to Japan.」
It continues to describe a sales environment in which alliances among major drugstore chains and retail price competition persist. - FY2019-Q1RestatedAnnual report
「In the OTC drug market, centered on drugstores, although business alliances among major drugstore chains and the impact of continued retail price competition for certain pharmaceuticals and products were factors, the analgesic and anti-inflammatory Roihi TsubokoTM series continued to perform strongly, supported in part by inbound demand.」
It continues to recognize that business alliances among major drugstore chains and retail price competition for pharmaceuticals and products are affecting the sales environment. - FY2018-Q2RestatedAnnual report
「In the OTC drug market, centered on drugstores, although business alliances among major drugstore chains and the impact of continued retail price competition for certain pharmaceuticals and products were factors, sales of the analgesic and anti-inflammatory product Roihi TsubokoTM continued to grow and remained strong.」
It continues to state that business alliances among major drugstore chains and retail price competition are affecting the sales environment. - FY2018-Q1RestatedAnnual report
「In the OTC drug market, centered on drugstores, although business alliances among major drugstore chains and the impact of continued retail price competition for certain pharmaceuticals and products were factors, sales of the analgesic and anti-inflammatory product Roihi TsubokoTM continued to grow and remained strong.」
It continues to state that business alliances among major drugstore chains and retail price competition for pharmaceuticals and products are affecting the sales environment. - FY2017RestatedAnnual report
「Deteriorating economic conditions and price declines caused by intensifying competition among companies in the market and other factors may adversely affect the Group's business performance and financial condition.」
It continues to identify the risk of price declines caused by economic deterioration and intensifying competition. - FY2017-Q3RestatedAnnual report
「In the OTC drug market, centered on drugstores, although business alliances among major drugstore chains and continued retail price competition for certain pharmaceuticals and products made the sales environment challenging,」
It continues to recognize that business alliances among major drugstore chains and retail price competition persist, making the sales environment challenging. - FY2017-Q2RestatedAnnual report
「Although business alliances among major drugstore chains and continued retail price competition for certain pharmaceuticals and products made the sales environment challenging,」
It continues to recognize that retail price competition persists and that the sales environment remains challenging. - FY2017-Q1RestatedAnnual report
「The sales environment remained challenging, with business alliances among major drugstore chains and continued retail price competition for certain pharmaceuticals and products.」
It states that retail price competition continues and that the sales environment remains challenging. - FY2016First statedAnnual report
「The Group's operating performance and financial condition may be adversely affected by price declines resulting from worsening economic conditions and intensifying competition among companies in the market.」
Against a backdrop of a product mix centered on consumables, the document cites price declines resulting from economic deterioration and intensified competition.